Tylenol maker and former Johnson & Johnson (JNJ) spinoff Kenvue Inc (NYSE:KVUE) is 16.7% higher to trade at $16.74, after Kimberly-Clark Corp (NASDAQ:KMB) agreed to purchase the pharma name for$48.70 billion in cash and stock. The deal is expected to close in the second half of 2026. Today's lift is well overdue for KVUE, trading at record lows of $14.02 on Oct. 30 and still down 22.8% year to date even after today's gap higher, poised to be its best day since August 2024. Options are surging in response 8 ...